Romark IVA - Digital PDF interaction 10.13

References
16
1. Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America Clinical Practices Guidelines for the Diagnosis and Management of Infectious Diarrhea.
Clin Infect Dis 2017;65(12):e45-e80.
2. Smalley W, Falck-Ytter C, Carrasco-Labra A, Wani S, Lytvyn L, Falck-Ytter Y. AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and
Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D). Gastroenterology 2019;157(3):851-854.
3. Beer KD, Collier SA, Du F, Gargano JW. Giardiasis Diagnosis and Treatment Practices Among Commercially Insured Persons in the United States. Clin Infect Dis
2017;64(9):1244-1250.
4. Attias E, Czinn SJ, Harro C, Munoz FM, Sockolow RE, Black JT. Emerging Issues in Managing Pediatric Parasitic Infections: An Assessment of Clinical and Epidemiological
Knowledge of Giardiasis and Cryptosporidiosis. Pediatr Therapeutics 2015;5(3):1-7.
5. Litleskare S, Rortveit G, Eide GE, Hanevik K, Langeland N, Wensaas K-A. Prevalence of Irritable Bowel Syndrome and Chronic Fatigue 10 Years After Giardia Infection.
Clin Gastroenterol H 2018;16(7): 1064-1072.e4.
6. Scallan E, Hoekstra RM, Angulo FJ, et al. Foodborne illness acquired in the United States—major pathogens. Emerg Infect Dis 2011;17:7–15.
7. Painter JE, Gargano JW, Collier SA, Yoder JS; Centers for Disease Control and Prevention. Giardiasis surveillance—United States, 2011–2012. MMWR Morb Mortal Wkly
Rep Suppl 2015; 64(3):15–25.
8. Chute CG, Smith RP, Baron JA. Risk factors for endemic giardiasis. Am J Public Health. 1987;77:585–7.
9. Hlavsa MC, Cikesh BL, Roberts VA, et al. Outbreaks Associated with Treated Recreational Water — United States, 2000–2014. MMWR Morb Mortal Wkly Rep
2018;67:547–551.
10. Painter JE, Hlavsa MC, Collier SA, et al. Cryptosporidiosis Surveillance, 2011-2012. MMWR Morb Mortal Wkly Rep Suppl 2015;64(3):1-13.
11. Okhuysen PC, et al. Infectivity of a Cryptosporidium parvum Isolate of Cervine Origin for Healthy Adults and Interferon-y Knockout Mice. J Infect Dis. 2002;185:1320-9.
12. Okhuysen PC, et al. Virulence of Three Distinct Cryptosporidium parvum Isolates for Healthy Adults. J Infect Dis. 1999;180:1275-81
13. ALINIA (nitazoxanide) Prescribing Information. June 2019.
14. Romark L.C., data on file.
Alinia is a registered trademark of Romark, L.C. Intended only for Healthcare Professionals of the United States of America. ©2020, Romark L.C. RM-AL-094-01V1 R10.20
*Indications
ALINIA ® for Oral Suspension (patients 1 year of age and older) and ALINIA Tablets (patients 12 years and older)
are indicated for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum.
Limitations of Use: ALINIA for Oral Suspension and ALINIA Tablets have not been shown to be effective for the
treatment of diarrhea caused by Cryptosporidium parvum in HIV-infected or immunodeficient patients.
Important Safety Information
• ALINIA Tablets and ALINIA for Oral Suspension are contraindicated in patients with a prior hypersensitivity
to nitazoxanide or any other ingredient in the formulations.